Transcatheter Intra-arterial Limb Infusion of Cisplatin for Extremity Osteosarcoma

NACompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

April 1, 2019

Study Completion Date

April 8, 2019

Conditions
Event-free SurvivalOverall SurvivalLocal-recurrence Free SurvivalPathological Response
Interventions
DRUG

Cisplatin

Cisplatin was administered intravenously or intraarterially after adequate IV hydration. For IA infusion, cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion; while for IV administration, it was given at 100-120 mg/m2 as 6-h infusions.

Trial Locations (1)

Unknown

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER

NCT03909776 - Transcatheter Intra-arterial Limb Infusion of Cisplatin for Extremity Osteosarcoma | Biotech Hunter | Biotech Hunter